Evidence map›Paper›PMID 38790050›Full record

ReviewCost effectiveness and resource allocation : C/E2024

Cost-effectiveness of differentiated care models that incorporate economic strengthening for HIV antiretroviral therapy adherence: a systematic review.

Annie Liang, Marta Wilson-Barthes, Omar Galárraga

Registry-linked trialAbstract readReview
In one paragraph

Review in Cost effectiveness and resource allocation : C/E, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04417127 (Harambee), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04417127 nacompletednot on this map

Harambee: Integrated Community-based HIV/NCD Care & Microfinance Groups in Kenya

TypeinterventionalSponsorBrown UniversityRan2020 to 2023Enrolled1,200ConditionsHIV/AIDS, Noncommunicable Diseases, Hypertension, DiabetesArmsIntegrated Community-Based (ICB) Care, Group-level Microfinance
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Annie LiangBrown University School of Public Health, Providence, RI, USA.
Marta Wilson-BarthesDepartment of Epidemiology, Brown University School of Public Health, Providence, RI, USA.ORCID http://orcid.org/0000-0002-9845-7142
Omar GalárragaDepartment of Health Services, Policy and Practice; and International Health Institute, Brown University School of Public Health, 121 South Main Street, Box G-S121-2, Providence, RI, USA. omar_galarraga@brown.edu.ORCID http://orcid.org/0000-0002-9985-9266

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH, DEBBIE M. CHENG · 1998 to 2026
$51.7M
Harambee: Integrated Community-Based HIV/NCD Care & Microfinance Groups in KenyaR01MH118075 · NIMH · BROWN UNIVERSITY · PI GALARRAGA, OMAR, GENBERG, BECKY LYNN · 2019 to 2023
$2.8M
National Institute of Allergy and Infectious Diseases of the National Institutes of Health through the Providence/Boston Center for Aids Research P30AI042853National Institute of Mental Health of the National Institutes of Health R01MH118075NIAID NIH HHS P30 AI042853NIMH NIH HHS R01 MH118075
6 · The paper itself

Abstract

backgroundThere is some evidence that differentiated service delivery (DSD) models, which use a client-centered approach to simplify and increase access to care, improve clinical outcomes among people living with HIV (PLHIV) in high HIV prevalence countries. Integrating economic strengthening tools (e.g., microcredit, cash transfers, food assistance) within DSD models can help address the poverty-related barriers to HIV antiretroviral therapy (ART). Yet there is minimal evidence of the cost-effectiveness of these types of multilevel care delivery models, which potentially prohibits their wider implementation.

methodsUsing a qualitative systematic review, this article synthesizes the literature surrounding the cost-effectiveness of differentiated service delivery models that employ economic strengthening initiatives to improve HIV treatment adherence in low- and middle-income countries. We searched three academic databases for randomized controlled trials and observational studies published from January 2000 through March 2024 in Sub-Saharan Africa. The quality of each study was scored using a validated appraisal system.

resultsEighty-nine full texts were reviewed and 3 met all eligibility criteria. Two of the three included articles were specific to adolescents living with HIV. Economic strengthening opportunities varied by care model, and included developmental savings accounts, microenterprise workshops, and cash and non-cash conditional incentives. The main drivers of programmatic and per-patient costs were ART medications, CD4 cell count testing, and economic strengthening activities.

conclusionAll economic evaluations in this review found that including economic strengthening as part of comprehensive differentiated service delivery was cost-effective at a willingness to pay threshold of at least 2 times the national per capita gross domestic product. Two of the three studies in this review focused on adolescents, suggesting that these types of care models may be especially cost-effective for youth entering adulthood. All studies were from the provider perspective, indicating that additional evidence is needed to inform the potential cost-savings of DSD and economic strengthening interventions to patients and society. Randomized trials testing the effectiveness of DSD models that integrate economic strengthening should place greater emphasis on costing these types of programs to inform the potential for bringing these types of multilevel interventions to scale.

Indexed as

Antiretroviral therapyConditional cash transferCost-effectivenessDifferentiated careDifferentiated service deliveryEconomic strengtheningHIVMicrofinanceSub-Saharan Africa

Identifiers

PMID38790050
PMCPMC11127452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.